Exosome Diagnostics, Inc has raised $20 million co-led by NGN Capital , (‘NGN’) New York, and Forbion Capital Partners , (‘Forbion’) Naarden, The Netherlands, to further develop and commercialise a series of next-generation body fluid based oncology diagnostics through its proprietary, exosome based technology platform. The transatlantic Company is establishing R&D and service operations in New York and Munich.
“We believe our exosome based technology offers a new medium for reproducible, highquality extraction of RNA from blood,” stated James McCullough, CEO of Exosome Diagnostics Inc. “Having NGN and Forbion, lead
this financing round, provides us with the strong global network necessary to accelerate product development and provide a comprehensive molecular companion diagnostic program to pharmaceutical partners.”
“The exosome technology platform combines great characteristics for cancer diagnostics and patient monitoring and is well positioned to have a major impact on cancer disease management in the future. We are delighted to join this experienced management team and are excited that this new platform will also be developed and rolled out in Europe using the proceeds of this financing round,” said Geert-Jan Mulder, M.D, General Partner
at Forbion Capital Partners.